Webinar
Transforming manual data curation through Agentic AI and LLMs: How Biorelate's Galactic AI™ will power the future of Drug Discovery
July 10, 2025 03:30 PM Europe/London
60min webinar
Thursday July 10th 3.30pm-4.30pm BST, 4.30-5.30pm CEST, 10.30-11.30am EDT, 7.30-8.30am PDT
This webinar will address the key business and research successes with AI from teams across large pharma and smaller biotechs, with exciting new insights and impactful examples.
KEYNOTE TALK: Alex Gutteridge, Vice President of Digital Biology at Novo Nordisk, will deliver the keynote talk at the end of the webinar: ‘Can machines really (help us) understand the biology of target discovery?’
Can’t make the webinar time? Registering will grant you early access to the recording link.
Follow Biorelate on LinkedIn for more drug discovery webinars
Alex Gutteridge
Alex has worked in the pharma and biotech industry applying data and AI to drug discovery and development for 15 years with positions at Pfizer, GSK, Lonza and Enedra and Dunad Therapeutics. Now at Novo Nordisk, Alex leads a multi-disciplinary group of computational biologists, geneticists and epidemiologists aiming to put data and AI at the centre of Novo Nordisk’s quest to defeat serious chronic diseases like diabetes and obesity.
Ben Sidders
Dr Ben Sidders, Chief Scientific Officer at Biorelate, has been working at the forefront of pharma data science for the last two decades. Formerly Executive Director and Head of Early Data Science within Oncology R&D at AstraZeneca, responsible for advancing the company’s understanding of disease through computational oncology, Ben also previously spent eight years at Pfizer, and has extensive experience of many aspects of drug discovery for major pharma. He is especially passionate about immuno-oncology, network biology and the role of bioinformatics within drug discovery. Ben has a PhD in Molecular Biology & Bioinformatics from the University of London where his thesis focused on the development of predictive markers for the diagnosis of asymptomatic Tuberculosis. He holds patents for two clinical diagnostics and has authored over 30 scientific publications.